Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion.

作者：U‐Ging Lo, Jiming Bao, Junjie Cen, Hsin‐Chih Yeh, Junhang Luo, Wanlong Tan, Jer‐Tsong Hsieh · 发表于：PubMed · 年份：2019 · 被引用次数：31 · 研究领域：Ferroptosis and cancer prognosis、Cancer, Hypoxia, and Metabolism、Cancer Immunotherapy and Biomarkers

Interferon is known as a pleiotropic factor in innate immunity, cancer immunity and therapy. Despite an objective short-term response of interferon (IFN) therapy in renal cell carcinoma (RCC) patients, the potential adverse effect of IFN on RCC cells is not fully understood. In this study, we demonstrate that IFNs can enhance RCC invasion via a new mechanism of IFIT5-mediated tumor suppressor microRNA (miRNA) degradation resulted in the elevation of Slug and ZEB1 and epithelial-to-mesenchymal transition (EMT). Clinically, a significant upregulation of IFNγ signaling pathway (such as IFNGR1, IFNGR2, STAT1 and STAT2) is observed in RCC patients with metastatic disease. Overall, this study provides a new mechanism of action of IFN-elicited canonical pathway in regulating suppressor miRNAs. Most importantly, it highlights the potential pro-metastatic effect of IFNs, which could undermine the clinical applicability of IFNs for treating RCC patients.